CLINICAL RESEARCH
Characteristics and clinical outcomes of patients with Sarcoidosis admitted for ST-elevation myocardial infarction in the United States: A propensity matched analysis from the National Inpatient Sample
1
Cardiac Sarcoidosis Services, Royal Brompton Hospital, London, United Kingdom
2
National Heart and Lung Institute, Imperial College London, United Kingdom
3
Dow University of Health Sciences, Karachi, Pakistan
4
Independent Researcher, Triolet
5
Northumbria Hospitals, NHS Foundation Trust, Newcastle upon Tyne, United Kingdom
6
Abington Hosp- Jefferson Health, Horsham, United States
7
One Brooklyn Health System/Interfaith Medical Ctr Program, Brooklyn, New York, United States
8
Department of Cardiology, Barts Heart Centre, London, United Kingdom
9
Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA
10
Center for Inherited Cardiovascular Diseases, Department of Cardiology, Wellspan Health, York, USA
These authors had equal contribution to this work
Submission date: 2024-01-23
Acceptance date: 2024-02-20
Publication date: 2024-03-08
Corresponding author
Sebastian Mactaggart
Northumbria Hospitals, NHS Foundation Trust, Newcastle upon Tyne, United Kingdom
Northumbria Hospitals, NHS Foundation Trust, Newcastle upon Tyne, United Kingdom
Arch Med Sci Atheroscler Dis 2024;9(1):47-55
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Sarcoidosis is a systemic inflammatory disorder characterised by non-caseating granulomas. Cardiac sarcoidosis (CS) normally causes conduction abnormalities, ventricular arrhythmias, and heart failure. Little is known about the characteristics and impact of sarcoidosis in patients admitted with ST-elevation myocardial infarction (STEMI). This study aims to fill this void.
Material and methods:
Utilising the National Inpatient Sample (NIS) database (2016–2020), individuals with STEMI were identified and categorised based on sarcoidosis presence whilst adjusting for confounders via logistic regression models.
Results:
Among 851,290 STEMI patients, 1215 had sarcoidosis. Before propensity matching, sarcoidosis patients were notably different in demographics and comorbidities compared to non-sarcoidosis patients. After propensity score matching (PSM), sarcoidosis patients were found to have a higher incidence of supraventricular tachycardia (SVT) (2.5% vs. 1.3%, p = 0.024) and acute kidney injury (AKI) (23.3% vs. 20.8%, aOR = 1.269, 95% CI: 1.02–1.58, p = 0.033) but a lower incidence of undergoing coronary artery bypass graft (CABG) (5.5% vs. 8.5%, aOR = 0.663; 95% CI: 0.472–0.931, p = 0.018), while no significant disparities were noted in PCI, cardiogenic shock, mortality, or mean length of stay (LOS).
Conclusions:
Using propensity-matched large real-world data of STEMI patients, sarcoidosis was associated with fewer cases of CABG and a greater incidence of AKI and SVT compared to non-sarcoidosis patients.
Sarcoidosis is a systemic inflammatory disorder characterised by non-caseating granulomas. Cardiac sarcoidosis (CS) normally causes conduction abnormalities, ventricular arrhythmias, and heart failure. Little is known about the characteristics and impact of sarcoidosis in patients admitted with ST-elevation myocardial infarction (STEMI). This study aims to fill this void.
Material and methods:
Utilising the National Inpatient Sample (NIS) database (2016–2020), individuals with STEMI were identified and categorised based on sarcoidosis presence whilst adjusting for confounders via logistic regression models.
Results:
Among 851,290 STEMI patients, 1215 had sarcoidosis. Before propensity matching, sarcoidosis patients were notably different in demographics and comorbidities compared to non-sarcoidosis patients. After propensity score matching (PSM), sarcoidosis patients were found to have a higher incidence of supraventricular tachycardia (SVT) (2.5% vs. 1.3%, p = 0.024) and acute kidney injury (AKI) (23.3% vs. 20.8%, aOR = 1.269, 95% CI: 1.02–1.58, p = 0.033) but a lower incidence of undergoing coronary artery bypass graft (CABG) (5.5% vs. 8.5%, aOR = 0.663; 95% CI: 0.472–0.931, p = 0.018), while no significant disparities were noted in PCI, cardiogenic shock, mortality, or mean length of stay (LOS).
Conclusions:
Using propensity-matched large real-world data of STEMI patients, sarcoidosis was associated with fewer cases of CABG and a greater incidence of AKI and SVT compared to non-sarcoidosis patients.
REFERENCES (58)
1.
Bokhari SRA, Zulfiqar H, Mansur A. Sarcoidosis. [Updated 2023 May 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/b....
2.
Moller DR, Rybicki BA, Hamzeh NY, et al. Genetic, immunologic, and environmental basis of sarcoidosis. Ann Am Thorac Soc 2017; 14 (Suppl 6): S429-36.
3.
Mahmoud AR, Dahy A, Dibas M, Abbas AS, Ghozy S, El-Qushayri AE. Association between sarcoidosis and cardiovascular comorbidity: a systematic review and meta-analysis. Heart Lung 2020; 49: 512-7.
4.
Hussain K, Shetty M. Cardiac sarcoidosis. [Updated 2023 Jan 9]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/b....
5.
Polverino F, Balestro E, Spagnolo P. Clinical presentations, pathogenesis, and therapy of sarcoidosis: state of the art. J Clin Med 2020; 9: 2363.
6.
Ungprasert P, Crowson CS, Matteson EL. Risk of cardiovascular disease among patients with sarcoidosis: a population-based retrospective cohort study, 1976-2013. Eur Respir J 2017; 49: 1601290.
7.
Rossides M, Kullberg S, Grunewald J, et al. Risk of acute myocardial infarction in sarcoidosis: a population-based cohort study from Sweden. Respir Med 2021; 188: 106624.
8.
Aikawa T, Koyanagawa K, Oyama-Manabe N, Anzai T. Cardiac sarcoidosis mimicking myocardial infarction: a comprehensive evaluation using computed tomography and positron emission tomography. J Nucl Cardiol 2020; 27: 1066-7.
9.
Bargagli E, Rosi E, Pistolesi M, Lavorini F, Voltolini L, Rottoli P. Increased risk of atherosclerosis in patients with sarcoidosis. Pathobiology 2017; 84: 258-63.
10.
Hoss S, Grinberg T, Eisen A. The interrelationship between sarcoidosis and atherosclerosis-complex yet rational. J Clin Med 2022; 11: 433.
11.
Taneja V, Stein DJ, Feuerstein JD. Impact of cirrhosis on outcomes in inflammatory bowel disease hospitalizations. J Clin Gastroenterol 2022; 56: 718-23.
12.
Elixhauser Comorbidity Software Refined For ICD-10-CM [Available from: https://hcup-us.ahrq.gov/tools....].
13.
Ramphul K, Sombans S, Verma R, et al. Characteristics and outcomes of 7620 multiple sclerosis patients admitted with COVID-19 in the United States. medRxiv 2023; 2023.02.15.23285994.
14.
Sawatari H, Chahal AA, Ahmed R, et al. Impact of cardiac implantable electronic devices on cost and length of stay in patients with surgical aortic valve replacement and transcutaneous aortic valve implantation. Am J Cardiol 2023; 192: 69-78.
15.
Elbadawi A, Elgendy IY, Omer M, et al. Outcomes of acute myocardial infarction in patients with familial hypercholesteremia. Am J Med 2021; 134: 992-1001.e4.
16.
HCUP National Inpatient Sample (NIS). Healthcare Cost and Utilization Project (HCUP). 2016, 2017, 2018, 2019, 2020. Agency for Healthcare Research and Quality, Rockville, MD. 2022 [Available from: https://www.hcup-us.ahrq.gov/n....
17.
Manansala M, Sami F, Arora S, Manadan AM. Reasons for hospitalization and all-cause mortality for adults with sarcoidosis. Am J Med Open 2023; 9: 100037.
18.
Schulte KJ, Mayrovitz HN. Myocardial infarction signs and symptoms: females vs. males. Cureus 2023; 15: e37522.
19.
Brito-Zerón P, Kostov B, Superville D, Baughman RP, Ramos-Casals M; Autoimmune Big Data Study Group. Geoepidemiological big data approach to sarcoidosis: geographical and ethnic determinants. Clin Exp Rheumatol 2019; 37: 1052-64.
21.
Hill SC, Abdus S. The effects of Medicaid on access to care and adherence to recommended preventive services. Health Serv Res 2021; 56: 84-94.
22.
Sharp M, Eakin M, Drent Marjolein. Socioeconomic determinants and disparities in sarcoidosis. Curr Opin Pulmonary Med 2020; 26: 568-73.
23.
Janot AC, Huscher D, Walker M, et al. Cigarette smoking and male sex are independent and age concomitant risk factors for the development of ocular sarcoidosis in a New Orleans sarcoidosis population. Sarcoidosis Vasc Diffuse Lung Dis 2015; 32: 138-43.
24.
Krell W, Bourbonnais JM, Kapoor R, et al. Effect of smoking and gender on pulmonary function and clinical features in sarcoidosis. Lung 2012; 190: 529-36.
25.
Hattori T, Konno S, Shijubo N, Ohmichi M, Nishimura M. Prevalence of smoking in sarcoidosis. Respirology 2013; 18: 1152-7.
26.
Gupta D, Singh AD, Agarwal R, Aggarwal AN, Joshi K, Jindal SK. Is tobacco smoking protective for sarcoidosis? A case-control study from North India. Sarcoidosis Vasc Diffuse Lung Dis 2010; 27: 19-26.
27.
Blanchet MR, Israël-Assayag E, Cormier Y. Inhibitory effect of nicotine on experimental hypersensitivity pneumonitis in vivo and in vitro. Am J Respir Crit Care Med 2004; 169: 903-9.
28.
Benmelouka AY, Abdelaal A, Mohamed ASE, et al. Association between sarcoidosis and diabetes mellitus: a systematic review and meta-analysis. Exp Rev Respir Med 2021; 12: 1589-95.
29.
Cozier YC, Coogan PF, Govender P, Berman JS, Palmer JR, Rosenberg L. Obesity and weight gain in relation to incidence of sarcoidosis in US black women: data from the Black Women’s Health Study. Chest 2015; 147: 1086-93.
30.
Ungprasert P, Crowson CS, Matteson EL. Smoking, obesity and risk of sarcoidosis: a population-based nested case-control study. Respir Med 2016; 120: 87-90.
31.
Procaccini C, Jirillo E, Matarese G. Leptin as an immunomodulator. Mol Aspects Med 2012; 33: 35-45.
32.
Hinz A, Brähler E, Möde R, Wirtz H, Bosse-Henck A. Anxiety and depression in sarcoidosis: the influence of age, gender, affected organs, concomitant diseases and dyspnea. Sarcoidosis Vasc Diffuse Lung Dis 2012; 29: 139-46.
33.
Goracci A, Fagiolini A, Martinucci M, et al. Quality of life, anxiety and depression in sarcoidosis. Gen Hosp Psychiatry 2008; 30: 441-5.
34.
Chang B, Steimel J, Moller DR, et al. Depression in sarcoidosis. Am J Respir Crit Care Med 2001; 163: 329-34.
36.
Kennedy PT, Zakaria N, Modawi SB, et al. Natural history of hepatic sarcoidosis and its response to treatment. Eur J Gastroenterol Hepatol 2006; 18: 721-6.
37.
Devaney K, Goodman ZD, Epstein MS, Zimmerman HJ, Ishak KG. Hepatic sarcoidosis. Clinicopathologic features in 100 patients. Am J Surg Pathol 1993; 17: 1272-80.
38.
Gupta S, Faughnan ME, Prud’homme GJ, Hwang DM, Munoz DG, Kopplin P. Sarcoidosis complicated by cirrhosis and hepatopulmonary syndrome. Can Respir J 2008; 15: 124-6.
39.
Malhotra A, Naniwadekar A, Sood G. Hepatobiliary and pancreatic: cirrhosis secondary to hepatic sarcoidosis. J Gastroenterol Hepatol 2008; 23: 1942.
40.
Rudzki C, Ishak KG, Zimmerman HJ. Chronic intrahepatic cholestasis of sarcoidosis. Am J Med 1975; 59: 373-87.
41.
Tadros M, Forouhar F, Wu GY. Hepatic sarcoidosis. J Clin Transl Hepatol 2013; 1: 87-93.
42.
Rosen Y, Moon S, Huang CT, Gourin A, Lyons HA. Granulomatous pulmonary angiitis in sarcoidosis. Arch Pathol Lab Med 1977; 101: 170-4.
43.
Bergner R, Hoffmann M, Waldherr R, Uppenkamp M. Frequency of kidney disease in chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20: 126-32.
44.
Ueda S, Murakami T, Ogino H, et al. Systemic sarcoidosis presenting with renal involvement caused by various sarcoidosis-associated pathophysiological conditions. Intern Med 2019; 58: 679-84.
45.
Mahfoudhi M, Mamlouk H, Turki S, Kheder A. Systemic sarcoidosis complicated of acute renal failure: about 12 cases. Pan Afr Med J 2015; 22: 75.
46.
Desai R, Kakumani K, Fong HK, et al. The burden of cardiac arrhythmias in sarcoidosis: a population-based inpatient analysis. Ann Transl Med 2018; 6: 330.
47.
Yasuda M, Iwanaga Y, Kato T, et al. Risk stratification for major adverse cardiac events and ventricular tachyarrhythmias by cardiac MRI in patients with cardiac sarcoidosis. Open Heart 2016; 3: e000437.
48.
Mahmoud AR, Dahy A, Dibas M, et al. Association between sarcoidosis and cardiovascular comorbidity: a systematic review and meta-analysis. Heart Lung 2020; 49: 512-7.
49.
Piccini JP, Hammill BG, Sinner MF, et al. Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993-2007. Circ Cardiovasc Qual Outcomes 2012; 5: 85-93.
50.
Ahmad M, Mehta P, Reddivari AKR, Mungee S. Percutaneous coronary intervention. In: StatPearls. StatPearls Publishing; 2023. Available from: http://www.ncbi.nlm.nih.gov/bo... Accessed December 17, 2023.
51.
Rapoport EA, Chidharla A, Mortoti SS. A case of cardiac sarcoidosis with concurrent myocardial ischemia. HeartRhythm Case Rep 2021; 7: 479-83.
52.
Lam CSP, Tolep KA, Metke MP, Glockner J, Cooper LT. Coronary sarcoidosis presenting as acute coronary syndrome. Clin Cardiol 2009; 32: E9-12.
53.
Rajkumar T, Lea-Henry T, Chacko B. Acute kidney injury as the presenting manifestation of sarcoidosis: a case series and review of literature. Nephrology 2018; 23: 597-600.
54.
Wang C, Liu H, Zhang T, et al. Acute kidney injury as a rare manifestation of pediatric sarcoidosis: a case report and systematic literature review. Clin Chim Acta 2019; 489: 68-74.
55.
Kikuchi H, Mori T, Rai T, Uchida S. Acute kidney injury caused by sarcoid granulomatous interstitial nephritis without extrarenal manifestations. CEN Case Rep 2015; 4: 212-7.
56.
Goyal A, Daneshpajouhnejad P, Hashmi MF, et al. Acute Kidney Injury. [Updated 2023 Feb 19]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/b....
57.
Ibrik O, Samon R, Roda A, et al. Sarcoidosis: diagnosis from the renal function and hypercalcaemia study. Nefrologia 2011; 31: 321-7.
58.
Manjunath V, Moeckel G, Dahl NK. Acute kidney injury in a patient with sarcoidosis: hypercalciuria and hypercalcemia leading to calcium phosphate deposition. Clin Nephrol 2013; 80: 151-5.
| ISSN: | 2451-0629 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
